mifepristone has been researched along with puromycin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourgeois, S; Gruol, DJ; Trotter, J; Zee, MC | 1 |
| Chiappetta, C; Hyder, SM; Stancel, GM | 1 |
| Callegari, EA; Chien, J; Drappeau, DD; Eyster, KM; Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Knapp, JR; Pan, B; Srinivasan, R; Telleria, CM; Terpstra, EJ; Wang, X; Zhang, L | 1 |
3 other study(ies) available for mifepristone and puromycin
| Article | Year |
|---|---|
Reversal of multidrug resistance by RU 486.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Colchicine; Daunorubicin; Dexamethasone; Drug Resistance; Female; Kinetics; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mifepristone; Phenotype; Puromycin; Structure-Activity Relationship; Thymoma; Thymus Neoplasms; Tumor Cells, Cultured; Verapamil | 1994 |
Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Blotting, Northern; Breast Neoplasms; Culture Media; Dactinomycin; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estrogens; Glucocorticoids; Hormone Antagonists; Humans; Lymphokines; Medroxyprogesterone Acetate; Mifepristone; Progesterone; Progestins; Protein Isoforms; Protein Synthesis Inhibitors; Puromycin; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
Topics: Activating Transcription Factor 4; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cinnamates; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mifepristone; Ovarian Neoplasms; Platinum; Proteasome Inhibitors; Protein Biosynthesis; Puromycin; RNA, Messenger; Signal Transduction; Thiourea; Tunicamycin; Unfolded Protein Response | 2016 |